Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Ertugliflozin is a potent and selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), primarily utilized in the management of type 2 diabetes mellitus. Marketed under the brand name Steglatro, this pharmaceutical agent functions by blocking SGLT2 in the proximal renal tubules of the kidneys. Under normal physiological conditions, SGLT2 reabsorbs the majority of filtered glucose back into the bloodstream. By inhibiting this transporter, Ertugliflozin promotes glycosuria, effectively lowering blood glucose levels through urinary excretion rather than increasing insulin secretion or sensitivity.
The chemical identity of Ertugliflozin is defined by its molecular formula, C19H23NO8S, and it carries the CAS registry number 1064757-12-3. Structurally, it belongs to the class of glucoside derivatives, specifically designed for high specificity toward the SGLT2 isoform over SGLT1, which minimizes gastrointestinal side effects often associated with less selective inhibitors. The drug is typically administered as an oral tablet once daily, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Clinical studies have demonstrated that Ertugliflozin significantly reduces HbA1c levels and body weight while offering a low risk of hypoglycemia when used without insulin secretagogues. Beyond glycemic control, emerging evidence suggests potential cardiovascular and renal protective benefits, aligning with the broader therapeutic goals of modern diabetes management. Patients are advised to maintain adequate hydration due to the increased osmotic diuresis caused by the drug. While generally well-tolerated, common adverse reactions may include genital mycotic infections and urinary tract infections, necessitating proper hygiene and monitoring. As part of the evolving landscape of antihyperglycemic therapies, Ertugliflozin represents a significant advancement in providing effective, mechanism-based treatment options for patients struggling to achieve glycemic targets through lifestyle modifications and traditional medications alone. Its unique profile makes it a valuable addition to comprehensive diabetes care protocols worldwide.